Petros Papadopoulos

Dr. Petros Papadopoulos

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JBJoseph Borg
Joseph Borg
PPPetros Papadopoulos
Petros Papadopoulos
MGMarianthi Georgitsi
Marianthi Georgitsi
LGLaura Gutiérrez
Laura Gutiérrez
GGGodfrey Grech
Godfrey Grech
SPSJAAK PHILIPSEN
SJAAK PHILIPSEN
Sjaak Philipsen and colleagues report that haploinsufficiency for KLF1 causes hereditary persistence of fetal hemoglobin in a large Maltese family. They further show that KLF1 is a key activator of BCL11A, which suppresses the expression of fetal hemoglobin. Hereditary persistence of fetal hemoglobin (HPFH) is characterized by persistent high levels of fetal hemoglobin (HbF) in adults. Several contributory factors, both genetic and environmental, have been identified1 but others remain elusive. HPFH was found in 10 of 27 members from a Maltese family. We used a genome-wide SNP scan followed by linkage analysis to identify a candidate region on chromosome 19p13.12–13. Sequencing revealed a nonsense mutation in the KLF1 gene, p.K288X, which ablated the DNA-binding domain of this key erythroid transcriptional regulator2. Only family members with HPFH were heterozygous carriers of this mutation. Expression profiling on primary erythroid progenitors showed that KLF1 target genes were downregulated in samples from individuals with HPFH. Functional assays suggested that, in addition to its established role in regulating adult globin expression, KLF1 is a key activator of the BCL11A gene, which encodes a suppressor of HbF expression3. These observations provide a rationale for the effects of KLF1 haploinsufficiency on HbF levels.

1 September 2011 in Blood
Verified
Journal Article
Closed access
PDF file
SLSten F. Libregts
Sten F. Libregts
LGLaura Gutiérrez
Laura Gutiérrez
ABAlexander M. de Bruin
Alexander M. de Bruin
FWFelix Martinus Wensveen
Felix Martinus Wensveen
PPPetros Papadopoulos
Petros Papadopoulos
Martijn A. NolteMartijn A. Nolte
Martijn A. Nolte
Anemia of chronic disease is a complication accompanying many inflammatory diseases. The proinflammatory cytokine IFN-γ has been implicated in this form of anemia, but the underlying mechanism remains unclear. Here we describe a novel mouse model for anemia of chronic disease, in which enhanced CD27-mediated costimulation strongly increases the formation of IFN-γ–producing effector T cells, leading to a progressive anemia. We demonstrate that the anemia in these mice is fully dependent on IFN-γ and that this cytokine reduces both the life span and the formation of red blood cells. Molecular analysis revealed that IFN-γ induces expression of the transcription factors of interferon regulatory factor-1 (IRF-1) and PU.1 in both murine and human erythroid precursors. We found that, on IFN-γ stimulation, IRF-1 binds to the promoter of SPI.1 (PU.1) and induces PU.1 expression, leading to inhibition of erythropoiesis. Notably, down-regulation of either IRF-1 or PU.1 expression is sufficient to overcome IFN-γ–induced inhibition of erythropoiesis. These findings reveal a molecular mechanism by which chronic exposure to IFN-γ induces anemia.

6 January 2013 in Nature
Verified
Journal Article
Closed access
CBChristoph Bieniossek
Christoph Bieniossek
GPGabor Papai
Gabor Papai
CSChristiane Schaffitzel
Christiane Schaffitzel
FGFrederic Garzoni
Frederic Garzoni
MCMaxime Chaillet
Maxime Chaillet
IBImre Berger
Imre Berger

20 March 2011 in Nature Genetics
Verified
Journal Article
Open access
PDF file
BGBelinda Giardine
Belinda Giardine
JBJoseph Borg
Joseph Borg
DHDouglas R Higgs
Douglas R Higgs
KPKenneth R Peterson
Kenneth R Peterson
SPSjaak Philipsen
Sjaak Philipsen
George PatrinosGeorge Patrinos
George Patrinos
George Patrinos and colleagues report the first implementation of the microattribution approach to systematically document genetic variation associated with a disease, applied here to hemoglobinopathies and thalassemias. They developed a series of connected locus-specific databases that document genotype and phenotype information for genetic variation in 37 globin and erythroid protein genes in individuals with globin disorders, with reciprocal attribution to data contributors. We developed a series of interrelated locus-specific databases to store all published and unpublished genetic variation related to hemoglobinopathies and thalassemia and implemented microattribution to encourage submission of unpublished observations of genetic variation to these public repositories. A total of 1,941 unique genetic variants in 37 genes, encoding globins and other erythroid proteins, are currently documented in these databases, with reciprocal attribution of microcitations to data contributors. Our project provides the first example of implementing microattribution to incentivise submission of all known genetic variation in a defined system. It has demonstrably increased the reporting of human variants, leading to a comprehensive online resource for systematically describing human genetic variation in the globin genes and other genes contributing to hemoglobinopathies and thalassemias. The principles established here will serve as a model for other systems and for the analysis of other common and/or complex human genetic diseases.

7 January 2021 in Leukemia
Verified
Journal Article
Closed access
PDF file
TBTiziano Barbui
Tiziano Barbui
AVAlessandro Maria Vannucchi
Alessandro Maria Vannucchi
AAAlberto Alvarez-Larran
Alberto Alvarez-Larran
AIAlessandra Iurlo
Alessandra Iurlo
AMArianna Masciulli
Arianna Masciulli
ARAlessandro Rambaldi
Alessandro Rambaldi

1 May 2015 in Haematologica
Verified
Journal Article
Closed access
PDF file
CAC. Al Assaf
C. Al Assaf
FOF. Van Obbergh
F. Van Obbergh
JBJ. Billiet
J. Billiet
ELE. Lierman
E. Lierman
TDT. Devos
T. Devos
PVP. Vandenberghe
P. Vandenberghe
The JAK2 V617F mutation, the thrombopoietin receptor MPL W515K/L mutation and the Calreticulin (CALR) mutations are mutually exclusive in essential thrombocythemia and support a novel molecular categorization of essential thrombocythemia. CALR mutations account for approximately 30 % of essential thrombocythemia cases. In a retrospective study, we have examined the frequency of MPL and CALR mutations in JAK2 V617F negative essential thrombocythemia (n=103). In addition, we compared the clinical phenotype and outcome of CALR mutant essential thrombocythemia with a cohort of JAK2 V617F positive essential thrombocythemia (n=57). CALR positive cases represented 63.7% of double negative essential thrombocythemia, and most carried CALR Type 1 or Type 2 indels. However, we also identified one patient, who was positive for both the JAK2 V617F and the CALR mutations. This study revealed that CALR mutant essential thrombocythemia is associated with younger age, higher platelet counts, lower erythrocyte counts, lower leukocyte counts, hemoglobin, hematocrit, and increased risk of progression to myelofibrosis in comparison with JAK2 V617F positive essential thrombocythemia. Analysis of the CALR mutant group according to indel type showed that CALR Type 1 deletion is strongly associated with male gender. CALR mutant patients had a better overall survival than JAK2 V617F positive patients, in particular patients of age 60 years or younger. In conclusion, this study on a Belgian cohort supports and extends the growing body of evidence that CALR mutant is phenotypically distinct from JAK2 V617F positive essential thrombocythemia, with regard to its clinical and hematological presentation as well as the overall survival.